Home › Research › Lewy body dementia
Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment
Katharina Bolsewig, Eline A.J. Willemse, Pascual Sánchez‐Juan, Alberto Rábano, Minerva Martinez-Castillo, James D. Doecke, Giovanni Bellomo, Lisa Vermunt et al.. Nature Communications, 2025-01-29
Topic: Brain proteins, microglia and lab models
Plain-language summary
DOPA Decarboxylase (DDC) has been proposed as a cerebrospinal fluid (CSF) biomarker with increased concentrations in Lewy body disorders (LBDs) and highest levels in patients receiving dopaminergic treatment. Here we evaluate plasma DDC, measured by proximity extension assay, and the effect of dopaminergic treatment in three independent LBD (with a focus on dementia with Lewy bodies (DLB) and Parkinson’s disease (PD)) cohorts: an autopsy-confirmed cohort (n = 71), a large multicenter, cross-dementia cohort (n = 1498) and a longitudinal cohort with detailed treatment information (n = 66, median follow-up time[IQR] = 4[4, 4] years). Plasma DDC was not altered between different LBDs and other disease groups or controls in absence of treatment. DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment. This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring. DOPA decarboxylase (DDC) in cerebrospinal fluid has great diagnostic potential for Lewy body disorders. Here, the authors report limited diagnostic potential of plasma DDC and a strong association with dopaminergic treatment.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 71 participants. Plasma DDC was not altered between different Lewy body disorders and other disease groups or controls in absence of treatment, and levels increased with higher dosages of dopaminergic treatment. Plasma DDC is of limited use as a diagnostic biomarker for Lewy body disorders but could be valuable for treatment monitoring.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bolsewig, K., Willemse, E. A., Sánchez‐Juan, P., Rábano, A., Martinez-Castillo, M., Doecke, J. D., et al. (2025). Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nature Communications. https://doi.org/10.1038/s41467-025-56293-z
Vancouver
Bolsewig K, Willemse EA, Sánchez‐Juan P, Rábano A, Martinez-Castillo M, Doecke JD, et al. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nature Communications. 2025. doi:10.1038/s41467-025-56293-z. PMID: 39881147.
BibTeX
@article{bolsewig2025-39881147,
author = {Bolsewig, Katharina and Willemse, Eline A.J. and Sánchez‐Juan, Pascual and Rábano, Alberto and Martinez-Castillo, Minerva and Doecke, James D. and Bellomo, Giovanni and Vermunt, Lisa and others},
title = {{Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment}},
journal = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-56293-z},
pmid = {39881147},
url = {https://doi.org/10.1038/s41467-025-56293-z}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- DDC levels increased over time in PD, being significantly associated to higher dosages of dopaminergic treatment.
- This emphasizes the need to consider treatment effect when analyzing plasma DDC, and suggests that plasma DDC, in contrast to CSF DDC, is of limited use as a diagnostic biomarker for LBD, but could be valuable for treatment monitoring.
Why it matters
Plasma DDC was not altered between different Lewy body disorders and other disease groups or controls in absence of treatment, and levels increased with higher dosages of dopaminergic treatment. Plasma DDC is of limited use as a diagnostic biomarker for Lewy body disorders but could be valuable for treatment monitoring.
Study details
- Study designlongitudinal study
- Participants71
- Evidence strengthModerate
How this study scored 63/100
Published in a leading specialty journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 1 / 4 | 71 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 20 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 6.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 11.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 20 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Marta del Campo: h-index 24 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | The University of Melbourne: institution h-index 1,342 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 26 institution(s) in 8 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39881147) |
| Free to read | 2 / 2 | Free to read |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1038/s41467-025-56293-z
- PubMed: 39881147
- Original source →
- Free full text: Nature Communications →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Lewy body dementia from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.